ClinicalTrials.gg
CompletedNCT05971940ACHIEVE-1Updated Sep 3, 2026Results posted

A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

A Phase 3 interventional study of Orforglipron and Placebo in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 89 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
559
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing orforglipron in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 4 of them phase 3. orforglipron · Diabetes Mellitus, Type 2.

Enrollment
7th of 15
559 · median 546
Started
2023
with 5 others
Phase 3
11 of 15
2 open now
Registered
6th of 15
by date
Lead sponsor
14 of 15
Eli Lilly and Company

Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 6 that started in 2023, is one of 11 in phase 3, and was the 6th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 15 studies testing orforglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing orforglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The study will last approximately 54 weeks.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have Type 2 Diabetes
  • Have ≥7.0% (53 mmol/mol) to ≤9.5% (80 mmol/mol) despite diet and exercise treatment, as determined by the central laboratory at screening.
  • Are naïve to insulin therapy except for gestational diabetes or ≤14 days use for acute treatment and have not used any oral or injectable antihyperglycemic medications during the 90 days preceding screening or between screening and randomization.
  • Are of stable weight (±5%) for at least 90 days prior to screening and agree to not initiate an intensive diet or exercise program during the study with the intent of reducing body weight other than the lifestyle and/or dietary measures for diabetes treatment.
  • Have a (BMI) ≥23.0 kilogram/square meter (kg/m²) at screening.

Exclusion criteria

Exclusion Criteria:

  • Have Type 1 Diabetes
  • Have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening, or between screening and randomization.
  • Currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
  • Have functional classification IV congestive heart failure.
  • Have acute or chronic pancreatitis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
559 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received once daily (QD) doses of orforglipron-matching placebo capsules administered orally, over a period of 40 weeks.

    Drug: Placebo

  • Experimental
    3 mg Orforglipron

    Participants received orforglipron capsules administered orally QD, starting at 1 milligram (mg) and increasing by 1 mg every 4 weeks until reaching a targeted dose of 3 mg, which was then maintained up to week 40.

    Drug: Orforglipron

  • Experimental
    12 mg Orforglipron

    Participants received orforglipron capsules administered orally QD, starting at 1 mg and increasing every 4 weeks until reaching a targeted dose of 12 mg, which was then maintained up to week 40.

    Drug: Orforglipron

  • Experimental
    36 mg Orforglipron

    Participants received orforglipron capsules administered orally QD, starting at 1 mg and increasing every 4 weeks until reaching a targeted dose of 36 mg, which was then maintained up to week 40.

    Drug: Orforglipron

Interventions

  • Administered orally

    Also known as: LY3502970

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c

    * Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over prolonged periods of time. * Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤ \[less than or equal to\] 8.0%, \> \[greater than\] 8.0%) and prior use of any antihyperglycemic medication (yes or no). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

Secondary outcomes

  1. Percentage of Participants With an HbA1c Target Value of < 7.0% (53 mmol/Mol)

    Percentage of participants with an HbA1c target value of less than (\<) 7.0% (53 millimoles per mole \[mmol/mol\]) was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and prior use of any antihyperglycemic medication (yes or no).

    Time frame: Week 40

  2. Percentage of Participants With an HbA1c Target Value of ≤6.5% (48 mmol/Mol)

    Percentage of Participants with an HbA1c target value of less than or equal to (≤) 6.5% (48 mmol/mol) was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and prior use of any antihyperglycemic medication (yes or no).

    Time frame: Week 40

  3. Change From Baseline in Fasting Serum Glucose (FSG)

    Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤ \[less than or equal to\] 8.0%, \> \[greater than\] 8.0%) and prior use of any antihyperglycemic medication (yes or no). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  4. Percent Change From Baseline in Body Weight

    Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and prior use of any antihyperglycemic medication (yes or no). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  5. Change From Baseline in Body Weight

    Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and prior use of any antihyperglycemic medication (yes or no). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  6. Percent Change From Baseline in Non-High-Density Lipoprotein (Non-HDL) Cholesterol

    Values represented under "Geometric LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis : log (Actual Measurement/Baseline) = country, treatment by time, log(baseline) by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and prior use of any antihyperglycemic medication (yes or no). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  7. Percent Change From Baseline in Triglycerides

    Values represented under "Geometric LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis : log (Actual Measurement/Baseline) = country, treatment by time, log(baseline) by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and prior use of any antihyperglycemic medication (yes or no). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  8. Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG)

    The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Post meal, Midday Premeal, Midday 2-hour Post meal, Evening Premeal, Evening 2-hour Post meal and Bedtime. The daily average was calculated as the average of the 7 blood glucose values collected on a particular day. Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and prior use of any antihyperglycemic medication (yes or no). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  9. Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction

    Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and prior use of any antihyperglycemic medication (yes or no).

    Time frame: Week 40

  10. Change From Baseline in Systolic Blood Pressure (SBP)

    Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and prior use of any antihyperglycemic medication (yes or no). Variance-covariance structure for change from baseline was unstructured.

    Time frame: Baseline, Week 40

  11. Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical-Component and Mental-Component) Scores

    The SF-36v2 is a participant-reported measure designed to assess health status using 36 items across 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.

    Time frame: Baseline, Week 40

07

Results

Posted Apr 22, 2026

Participant flow

Participant flow — Overall Study
MilestonePlacebo3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Started138143137141
Received at least one dose of study drug138143137141
Completed131134125136
Not completed79125
Withdrew: Withdrawal by subject3431
Withdrew: Death1210
Withdrew: Physician decision1010
Withdrew: Site terminated by sponsor1001
Withdrew: Protocol deviation1000
Withdrew: Adverse event0102
Withdrew: Lost to follow-up0141
Withdrew: Participant not entering safety follow-up0100
Withdrew: Non-compliance with study drug0010
Withdrew: Other - as reported by the investigator0020

Outcome measures

PrimaryChange From Baseline in HbA1c

* Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over prolonged periods of time. * Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤ \[less than or equal to\] 8.0%, \> \[greater than\] 8.0%) and prior use of any antihyperglycemic medication (yes or no). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in HbA1c
percentage of HbA1cPlacebo3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Change From Baseline in HbA1c-0.15 ± 0.113-1.26 ± 0.114-1.59 ± 0.087-1.45 ± 0.104
Statistical analysis
  • Placebo vs 3 mg Orforglipron · Mixed Models Analysis · p = <.001 · Least square (ls) mean difference (net): -1.12 · 95% CI -1.43 to -0.80
  • Placebo vs 12 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -1.44 · 95% CI -1.72 to -1.16
  • Placebo vs 36 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -1.30 · 95% CI -1.61 to -1.00
SecondaryPercentage of Participants With an HbA1c Target Value of < 7.0% (53 mmol/Mol)

Percentage of participants with an HbA1c target value of less than (\<) 7.0% (53 millimoles per mole \[mmol/mol\]) was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and prior use of any antihyperglycemic medication (yes or no).

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With an HbA1c Target Value of < 7.0% (53 mmol/Mol)
percentage of participantsPlacebo3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Percentage of Participants With an HbA1c Target Value of < 7.0% (53 mmol/Mol)37.1178.1581.2578.99
Statistical analysis
  • Placebo vs 3 mg Orforglipron · Regression, Logistic · p = <.001 · Risk difference (rd): 44.90 · 95% CI 34.41 to 55.39
  • Placebo vs 12 mg Orforglipron · Regression, Logistic · p = <.001 · Risk difference (rd): 48.22 · 95% CI 37.50 to 58.93
  • Placebo vs 36 mg Orforglipron · Regression, Logistic · p = <.001 · Risk difference (rd): 46.94 · 95% CI 36.61 to 57.28
SecondaryPercentage of Participants With an HbA1c Target Value of ≤6.5% (48 mmol/Mol)

Percentage of Participants with an HbA1c target value of less than or equal to (≤) 6.5% (48 mmol/mol) was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and prior use of any antihyperglycemic medication (yes or no).

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With an HbA1c Target Value of ≤6.5% (48 mmol/Mol)
percentage of participantsPlacebo3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Percentage of Participants With an HbA1c Target Value of ≤6.5% (48 mmol/Mol)18.5666.3968.7568.91
Statistical analysis
  • Placebo vs 3 mg Orforglipron · Regression, Logistic · p = <.001 · Risk difference (rd): 48.01 · 95% CI 38.47 to 57.55
  • Placebo vs 12 mg Orforglipron · Regression, Logistic · p = <.001 · Risk difference (rd): 48.79 · 95% CI 39.11 to 58.47
  • Placebo vs 36 mg Orforglipron · Regression, Logistic · p = <.001 · Risk difference (rd): 52.48 · 95% CI 42.88 to 62.09
SecondaryChange From Baseline in Fasting Serum Glucose (FSG)

Values represented under "Least Squares (LS) Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤ \[less than or equal to\] 8.0%, \> \[greater than\] 8.0%) and prior use of any antihyperglycemic medication (yes or no). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · milligram per deciliter (mg/dL)
Change From Baseline in Fasting Serum Glucose (FSG)
milligram per deciliter (mg/dL)Placebo3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Change From Baseline in Fasting Serum Glucose (FSG)-1.1 ± 4.01-30.6 ± 3.66-37.4 ± 3.08-37.8 ± 2.94
Statistical analysis
  • Placebo vs 3 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -29.4 · 95% CI -40.1 to -18.7
  • Placebo vs 12 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -36.3 · 95% CI -46.4 to -26.3
  • Placebo vs 36 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -36.7 · 95% CI -46.6 to -26.8
SecondaryPercent Change From Baseline in Body Weight

Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and prior use of any antihyperglycemic medication (yes or no). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Body Weight
percent changePlacebo3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Percent Change From Baseline in Body Weight-1.6 ± 0.43-4.7 ± 0.47-6.1 ± 0.55-7.9 ± 0.58
Statistical analysis
  • Placebo vs 3 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -3.1 · 95% CI -4.4 to -1.8
  • Placebo vs 12 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -4.5 · 95% CI -5.9 to -3.1
  • Placebo vs 36 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -6.3 · 95% CI -7.7 to -4.8
SecondaryChange From Baseline in Body Weight

Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and prior use of any antihyperglycemic medication (yes or no). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Body Weight
kilogram (kg)Placebo3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Change From Baseline in Body Weight-1.3 ± 0.36-4.4 ± 0.43-5.5 ± 0.49-7.3 ± 0.55
Statistical analysis
  • Placebo vs 3 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -3.1 · 95% CI -4.2 to -2.0
  • Placebo vs 12 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -4.2 · 95% CI -5.5 to -3.0
  • Placebo vs 36 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -6.0 · 95% CI -7.3 to -4.6
SecondaryPercent Change From Baseline in Non-High-Density Lipoprotein (Non-HDL) Cholesterol

Values represented under "Geometric LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis : log (Actual Measurement/Baseline) = country, treatment by time, log(baseline) by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and prior use of any antihyperglycemic medication (yes or no). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Geometric least squares mean · percent change
Percent Change From Baseline in Non-High-Density Lipoprotein (Non-HDL) Cholesterol
percent changePlacebo3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Percent Change From Baseline in Non-High-Density Lipoprotein (Non-HDL) Cholesterol3.19 ± 2.085-1.82 ± 2.193-4.80 ± 2.273-7.91 ± 1.760
Statistical analysis
  • Placebo vs 3 mg Orforglipron · Mixed Models Analysis · p = 0.100 · Geometric ls mean difference (net): -4.85 · 95% CI -10.33 to 0.96
  • Placebo vs 12 mg Orforglipron · Mixed Models Analysis · p = 0.010 · Geometric ls mean difference (net): -7.75 · 95% CI -13.26 to -1.88
  • Placebo vs 36 mg Orforglipron · Mixed Models Analysis · p = <.001 · Geometric ls mean difference (net): -10.76 · 95% CI -15.53 to -5.71
SecondaryPercent Change From Baseline in Triglycerides

Values represented under "Geometric LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis : log (Actual Measurement/Baseline) = country, treatment by time, log(baseline) by time by treatment, and strata by time by treatment in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and prior use of any antihyperglycemic medication (yes or no). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Geometric least squares mean · percent change
Percent Change From Baseline in Triglycerides
percent changePlacebo3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Percent Change From Baseline in Triglycerides0.0 ± 3.56-9.1 ± 3.61-16.5 ± 3.06-14.0 ± 2.84
Statistical analysis
  • Placebo vs 3 mg Orforglipron · Mixed Models Analysis · p = 0.072 · Geometric ls mean difference (net): -9.2 · 95% CI -18.3 to 0.9
  • Placebo vs 12 mg Orforglipron · Mixed Models Analysis · p = <.001 · Geometric ls mean difference (net): -16.5 · 95% CI -24.5 to -7.7
  • Placebo vs 36 mg Orforglipron · Mixed Models Analysis · p = 0.002 · Geometric ls mean difference (net): -14.0 · 95% CI -22.0 to -5.3
SecondaryChange From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG)

The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Post meal, Midday Premeal, Midday 2-hour Post meal, Evening Premeal, Evening 2-hour Post meal and Bedtime. The daily average was calculated as the average of the 7 blood glucose values collected on a particular day. Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and prior use of any antihyperglycemic medication (yes or no). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · milligram per deciliter (mg/dL)
Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG)
milligram per deciliter (mg/dL)Placebo3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG)-17.6 ± 3.99-43.6 ± 3.73-56.0 ± 2.29-58.1 ± 1.80
Statistical analysis
  • Placebo vs 3 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -26.0 · 95% CI -36.8 to -15.1
  • Placebo vs 12 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -38.4 · 95% CI -47.7 to -29.2
  • Placebo vs 36 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -40.5 · 95% CI -49.3 to -31.7
SecondaryPercentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction

Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression with analysis country, treatment by baseline and treatment by strata in the model. Strata were defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and prior use of any antihyperglycemic medication (yes or no).

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction
percentage of participantsPlacebo3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction14.5847.0658.5666.39
Statistical analysis
  • Placebo vs 3 mg Orforglipron · Regression, Logistic · p = <.001 · Risk difference (rd): 25.36 · 95% CI 14.25 to 36.47
  • Placebo vs 12 mg Orforglipron · Regression, Logistic · p = <.001 · Risk difference (rd): 37.28 · 95% CI 26.05 to 48.50
  • Placebo vs 36 mg Orforglipron · Regression, Logistic · p = <.001 · Risk difference (rd): 44.80 · 95% CI 33.54 to 56.06
SecondaryChange From Baseline in Systolic Blood Pressure (SBP)

Values represented under "LS Mean" are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a MMRM with analysis country, treatment by time, baseline by time by treatment, and strata by time by treatment in the model. Strata was defined by joint levels of baseline HbA1c (≤8.0%, \>8.0%) and prior use of any antihyperglycemic medication (yes or no). Variance-covariance structure for change from baseline was unstructured.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP)
millimeters of mercury (mmHg)Placebo3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Change From Baseline in Systolic Blood Pressure (SBP)-0.5 ± 0.88-3.2 ± 0.91-6.1 ± 0.97-6.0 ± 0.91
Statistical analysis
  • Placebo vs 3 mg Orforglipron · Mixed Models Analysis · p = 0.031 · Ls mean difference (net): -2.7 · 95% CI -5.2 to -0.2
  • Placebo vs 12 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -5.6 · 95% CI -8.2 to -3.0
  • Placebo vs 36 mg Orforglipron · Mixed Models Analysis · p = <.001 · Ls mean difference (net): -5.5 · 95% CI -8.0 to -3.0
SecondaryChange From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical-Component and Mental-Component) Scores

The SF-36v2 is a participant-reported measure designed to assess health status using 36 items across 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · T-score
Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical-Component and Mental-Component) Scores
T-scorePlacebo3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Physical Component Score2.25 ± 0.5922.06 ± 0.5132.21 ± 0.5741.58 ± 0.632
Mental Component Score0.09 ± 0.6890.11 ± 0.687-0.37 ± 0.587-0.46 ± 0.777
Statistical analysis
  • Placebo vs 3 mg Orforglipron · ANCOVA · p = 0.801 · Ls mean difference (net): -0.19 · 95% CI -1.63 to 1.26
  • Placebo vs 12 mg Orforglipron · ANCOVA · p = 0.964 · Ls mean difference (net): -0.04 · 95% CI -1.61 to 1.54
  • Placebo vs 36 mg Orforglipron · ANCOVA · p = 0.410 · Ls mean difference (net): -0.66 · 95% CI -2.25 to 0.92
  • Placebo vs 3 mg Orforglipron · ANCOVA · p = 0.990 · Ls mean difference (net): 0.01 · 95% CI -1.89 to 1.91
  • Placebo vs 12 mg Orforglipron · ANCOVA · p = 0.592 · Ls mean difference (net): -0.46 · 95% CI -2.17 to 1.24
  • Placebo vs 36 mg Orforglipron · ANCOVA · p = 0.571 · Ls mean difference (net): -0.56 · 95% CI -2.49 to 1.37

Adverse events

Collected over Baseline to end of safety follow-up (up to 42 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/138 (0.7%)5/138 (3.6%)110/138 (79.7%)
3 mg Orforglipron2/143 (1.4%)8/143 (5.6%)118/143 (82.5%)
12 mg Orforglipron1/137 (0.7%)7/137 (5.1%)118/137 (86.1%)
36 mg Orforglipron0/141 (0%)4/141 (2.8%)123/141 (87.2%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventPlacebo3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
Ectopic pregnancyPregnancy, puerperium and perinatal conditions0/630/631/710/72
Cardiac failureCardiac disorders0/1380/1431/1370/141
CellulitisInfections and infestations0/1380/1431/1370/141
Diabetic foot infectionInfections and infestations0/1380/1431/1370/141
InfluenzaInfections and infestations0/1380/1431/1370/141
SepsisInfections and infestations0/1380/1431/1370/141
Septic shockInfections and infestations1/1380/1431/1370/141
DehydrationMetabolism and nutrition disorders0/1380/1431/1370/141
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders0/1380/1431/1370/141
Ischaemic strokeNervous system disorders0/1380/1431/1370/141
Most frequent other events
Showing 10 of 415
Most frequent other events
EventPlacebo3 mg Orforglipron12 mg Orforglipron36 mg Orforglipron
HyperglycaemiaMetabolism and nutrition disorders37/13811/1436/1379/141
DiarrhoeaGastrointestinal disorders13/13827/14329/13736/141
DyspepsiaGastrointestinal disorders10/13817/14329/13722/141
NauseaGastrointestinal disorders3/13818/14326/13724/141
Diabetic retinopathyEye disorders21/13821/1438/13724/141
ConstipationGastrointestinal disorders5/13812/14323/13720/141
VomitingGastrointestinal disorders2/1387/1439/13720/141
Decreased appetiteMetabolism and nutrition disorders3/1385/14314/13717/141
Abdominal distensionGastrointestinal disorders11/1386/1437/13716/141
HeadacheNervous system disorders8/13810/1438/13711/141

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Placebo3 mg Orforglipron12 mg Orforglipron36 mg OrforglipronTotal
Mean53.3 ± 12.5153.3 ± 11.2854.1 ± 11.7652.8 ± 11.8353.4 ± 11.83
Sex: Female, Male
Sex: Female, Male(Participants)Placebo3 mg Orforglipron12 mg Orforglipron36 mg OrforglipronTotal
Female63637172269
Male75806669290
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo3 mg Orforglipron12 mg Orforglipron36 mg OrforglipronTotal
Hispanic or Latino56575555223
Not Hispanic or Latino82868285335
Unknown or Not Reported00011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo3 mg Orforglipron12 mg Orforglipron36 mg OrforglipronTotal
American Indian or Alaska Native35353835143
Asian61635962245
Native Hawaiian or Other Pacific Islander00000
Black or African American389424
White38373040145
More than one race00101
Unknown or Not Reported10001
Region of Enrollment
Region of Enrollment(Participants)Placebo3 mg Orforglipron12 mg Orforglipron36 mg OrforglipronTotal
China1314121251
India2121192283
Japan25262525101
Mexico38404140159
United States41424042165
HemoglobinA1c (HbA1c)
HemoglobinA1c (HbA1c)(Percentage of HbA1c)Placebo3 mg Orforglipron12 mg Orforglipron36 mg OrforglipronTotal
Mean7.96 ± 0.897.93 ± 0.867.98 ± 0.918.07 ± 0.907.99 ± 0.89
08

Study locations

89 sites
  • Syed Research Consultants Llc
    Sheffield, Alabama 35660, United States
  • Epic Medical Research - Surprise
    Surprise, Arizona 85378, United States
  • Quality of Life Medical & Research Center
    Tucson, Arizona 85712, United States
  • Neighborhood Healthcare Institute of Health
    Escondido, California 92025, United States
  • Velocity Clinical Research, Huntington Park
    Huntington Park, California 90255, United States
  • Ark Clinical Research
    Long Beach, California 90815, United States
  • Velocity Clinical Research, Westlake
    Los Angeles, California 90057, United States
  • Infinity Clinical Research - Norco
    Norco, California 92860, United States
  • Norcal Endocrinology & Internal Medicine
    San Ramon, California 94583, United States
  • University Clinical Investigators, Inc.
    Tustin, California 92780, United States
  • Connecticut Clinical Research - Cromwell
    Cromwell, Connecticut 06416, United States
  • Invictus Clinical Research Group
    Coconut Creek, Florida 33073, United States
  • Hillcrest Medical Research
    DeLand, Florida 32720, United States
  • K2 Medical Research
    Maitland, Florida 32751, United States
  • Global Health Research Center, Inc.
    Miami Lakes, Florida 33016, United States
  • West Orange Endocrinology
    Ocoee, Florida 34761, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • Rophe Adult and Pediatric Medicine/SKYCRNG
    Union City, Georgia 30291, United States
  • Family First Medical Center
    Idaho Falls, Idaho 83404, United States
  • American Health Network of Indiana, LLC - Muncie
    Muncie, Indiana 47304, United States
  • Tekton Research - Wichita
    Wichita, Kansas 67218, United States
  • Alliance for Multispecialty Research, LLC
    New Orleans, Louisiana 70119, United States
  • Revival Research Institute
    Dearborn, Michigan 48126, United States
  • Billings Clinic
    Billings, Montana 59101, United States
  • Ellipsis Research Group - Brooklyn - 7th Street
    Brooklyn, New York 11215, United States
  • Central New York Clinical Research
    Manlius, New York 13104, United States
  • Monroe Biomedical Research
    Monroe, North Carolina 28112, United States
  • Lucas Research - New Bern
    New Bern, North Carolina 28562, United States
  • Centricity Research Dublin Multispecialty
    Dublin, Ohio 43016, United States
  • Alliance for Multispecialty Research, LLC
    Norman, Oklahoma 73069, United States
  • The Corvallis Clinic, P.C.
    Corvallis, Oregon 97330, United States
  • Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair
    Pittsburgh, Pennsylvania 15243, United States
  • Preferred Primary Care Physicians
    Uniontown, Pennsylvania 15401, United States
  • The Research Center of The Upstate
    Greenville, South Carolina 29607, United States
  • MDFirst Research, LLC
    Lancaster, South Carolina 29720, United States
  • The Jackson Clinic
    Jackson, Tennessee 38305, United States
  • Velocity Clinical Research, Dallas
    Dallas, Texas 75230, United States
  • Juno Research
    Houston, Texas 77040, United States
  • Endocrine Ips, Pllc
    Houston, Texas 77079, United States
  • Amir A Hassan, MD, PA
    Houston, Texas 77089, United States
  • Burke Internal Medicine and Research
    Burke, Virginia 22015, United States
  • Wannan Medical College Yijishan Hospital
    Wuhu, Anhui 241001, China
  • Luhe Hospital
    Beijing, Beijing Municipality 100000, China
  • Beijing Hospital
    Beijing, Beijing Municipality 100730, China
  • Beijing Pinggu District Hospital
    Beijing, Beijing Municipality 101200, China
  • Shunde Hospital of Southern Medical Univesity
    Foshan, Guangdong 528399, China
  • Huizhou Municipal Central Hospital
    Huizhou, Guangdong 516001, China
  • The Fourth Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • Nanyang First People's Hospital
    Nanyang, Henan 473001, China
  • The Second Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450014, China
  • Nanjing First Hospital
    Nanjing, Jiangsu 210006, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212000, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Pudong New Area People's Hospital Shanghai
    Shanghai, Shanghai Municipality 201200, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • GMERS Medical College and General Hospital
    Vadodara, Gujarat 390021, India
  • M S Ramaiah Medical College and Hospitals
    Bangalore, Karnataka 560054, India
  • Medstar Speciality Hospital
    Bangalore, Karnataka 560092, India
  • BSES MG Hospital
    Mumbai, Maharashtra 400058, India
  • All India Institute of Medical Sciences (AIIMS) - Nagpur
    Nagpur, Maharashtra 441108, India
  • Grant Medical Foundation - Ruby Hall Clinic
    Pune, Maharashtra 411001, India
  • Madras Diabetes Research Foundation
    Chennai, Tamil Nadu 600086, India
  • Kumudini Devi Diabetes Research Center
    Hyderabad, Telangana 500072, India
  • Institute of Post Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital
    Kolkata, West Bengal 700020, India
  • Tokuyama Clinic
    Mihama-ku,Chiba City, Chiba 261-0004, Japan
  • Steel Memorial Yahata Hospital
    Kitakyushu, Fukuoka 805-8508, Japan
  • Hasegawa Medical Clinic
    Chitose, Hokkaido 066-0032, Japan
  • MinamiAkatsukaClinic
    Mito, Ibaraki 311-4153, Japan
  • Iwamoto Clinic
    Zentsujichó, Kagawa-ken 765-0071, Japan
  • Hayashi Diabetes Internal Medicine Clinic
    Chigasaki, Kanagawa 253-0044, Japan
  • Medical Corporation Yuga Tsuruma Kaneshiro Diabetes Clinic
    Yamato-shi, Kanagawa 242-0004, Japan
  • Medical Corporation Heishinkai OCROM Clinic
    Suita-shi, Osaka 565-0853, Japan
  • The Institute of Medical Science, Asahi Life Foundation
    Chuo-ku, Tokyo 103-0002, Japan
  • Tokyo-Eki Center-building Clinic
    Chuo-ku, Tokyo 103-0027, Japan
  • Fukuwa Clinic
    Chuo-ku, Tokyo 104-0031, Japan
  • Heishinkai Medical Group ToCROM Clinic
    Shinjuku-ku, Tokyo 160-0008, Japan
  • Morinaga Ueno Clinic
    Kumamoto, 860-0863, Japan
  • Abe Clinic
    Ōita, 870-0039, Japan
  • Unidad de Investigaci�n Cl�nica Cardiometabolica de Occidente
    Guadalajara, Jalisco 44150, Mexico
  • Centro de Investigacion Medica Integral
    Guadalajara, Jalisco 44160, Mexico
  • Salud Cardiovascular
    Guadalajara, Jalisco 44860, Mexico
  • Centro de Investigacion Medica de Occidente, S.C.
    Zapopan, Jalisco 44260, Mexico
  • Investigacion En Salud Y Metabolismo S.C / Nutricion Clinica / Unidad de Base de Datos
    Chihuahua City, 31110, Mexico
  • PanAmerican Clinical Research - Querétaro - Avenida Antea
    Querétaro, 76100, Mexico
  • Instituto Veracruzano en Investigación Clínica S.C.
    Veracruz, 91851, Mexico
  • FAICIC S. de R.L. de C.V.
    Veracruz, 91900, Mexico
  • Puerto Rico Health Institute
    Dorado, 00646, Puerto Rico
  • Advance Medical Research Center
    San Juan, 00926, Puerto Rico
09

References and documents

Publications

  • Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, Liu R, Li J, Fernandez Lando L, Denning M, Ludwig L, Chen Y; ACHIEVE-1 Trial Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025 Sep 18;393(11):1065-1076. doi: 10.1056/NEJMoa2505669. Epub 2025 Jun 21. PubMed 40544435 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual participant level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Apr 2025, 19 months.

Results were first posted in Apr 2026, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 19 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2023
First posted
Aug 2, 2023
StartActual
Aug 9, 2023
Primary completionActual
Apr 3, 2025
CompletionActual
Apr 3, 2025
Results first posted
Apr 22, 2026
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05971940
Responsible party
Sponsor
First posted
Aug 2, 2023
Start date
Aug 9, 2023
Primary completion
Apr 3, 2025
Completion
Apr 3, 2025
Results posted
Apr 22, 2026
Last update
Sep 3, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion